71636-62-9|SKF-80723 HBr|9-Bromo-5-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol hydrobromide|-范德生物科技公司

SKF-80723 HBr

NMR下载 COA and HPLC MSDS下载
names：
9-Bromo-5-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol hydrobromide
CAS号：
71636-62-9
MDL Number：
MF(分子式)： C16H17Br2NO2 MW(分子量)： 415.125
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	9-Bromo-5-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol hydrobromide
英文别名	SKF-80723 HBr; SKF 80723 HBr; SKF80723 HBr; SKF-80723 Hydrobromide; SKF80723 Hydrobromide; SKF 80723 Hydrobromide
CAS号	71636-62-9
Inchi	InChI=1S/C16H16BrNO2.BrH/c17-15-11-6-7-18-9-13(10-4-2-1-3-5-10)12(11)8-14(19)16(15)20;/h1-5,8,13,18-20H,6-7,9H2;1H
InchiKey	NYAMJPQXUKPMIX-UHFFFAOYSA-N
分子式 Formula	C16H17Br2NO2
分子量 Molecular Weight	415.125
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	SKF-80723 HBr(CAS:71636-62-9):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	SKF-80723 HBr is a D1 receptor agonist. In rats with a unilateral 6-hydroxydopamine (6-OHDA) lesion of the medial forebrain bundle, SKF-80723 HBr strongly potentiated the contralateral circling induced by quinpirole.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Gnanalingham KK, Hunter AJ, Jenner P, Marsden CD. The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease. Psychopharmacology (Berl). 1995 Feb;117(3):287-97. PubMed PMID: 7770604.

[2]Starr MS, Starr BS. Seizure promotion by D1 agonists does not correlate with other dopaminergic properties. J Neural Transm Park Dis Dement Sect. 1993;6(1):27-34. PubMed PMID: 8105796.

[3] Gnanalingham KK, Hunter AJ, Jenner P, Marsden CD. Stimulation of adenylate cyclase activity by benzazepine D-1 dopamine agonists with varying efficacies in the 6-hydroxydopamine lesioned rat--relationship to circling behaviour. Biochem Pharmacol. 1995 May 11;49(9):1185-93. PubMed PMID: 7763300.

[4] Alam AM, Starr MS. D1 agonists suppress zero Mg(2+)-induced epileptiform activity in the rat cingulate cortex slice. Neuroreport. 1993 Oct 25;5(1):78-80. PubMed PMID: 7506591.

[5] Granata R, Wenning GK, Jolkkonen J, Jenner P, Marsden CD. Effect of repeated administration of dopamine agonists on striatal neuropeptide mRNA expression in rats with a unilateral nigral 6-hydroxydopamine lesion. J Neural Transm (Vienna). 1996;103(3):249-60. PubMed PMID: 8739837.

6: Gnanalingham KK, Hunter AJ, Jenner P, Marsden CD. Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease--the differential effects of D1 dopamine antagonists in the primate. Psychopharmacology (Berl). 1995 Feb;117(4):403-12. PubMed PMID: 7604140.7: Gnanalingham KK, Erol DD, Hunter AJ, Smith LA, Jenner P, Marsden CD. Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset. Psychopharmacology (Berl). 1995 Feb;117(3):275-86. PubMed PMID: 7770603.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开